Quantum BioPharma Ltd. announced positive results from a clinical trial of its dietary supplement, unbuzzd™, demonstrating its efficacy in accelerating alcohol metabolism and reducing intoxication and hangover symptoms. The double-blind, placebo-controlled crossover study involved participants aged 21-43 who consumed unbuzzd™ after alcohol. Results showed statistically significant improvements in BAC reduction, alertness, and hangover symptoms within 30 minutes, with no reported side effects.
This news holds significant implications for the dietary supplement market and potentially for public health. The rapid and substantial reduction in blood alcohol content suggests unbuzzd™ could offer a practical solution for individuals seeking to mitigate the negative effects of alcohol consumption. Furthermore, the demonstrated improvement in alertness and reduction in hangover symptoms could lead to increased productivity and improved well-being for consumers. This creates a new market category within the supplement industry, addressing a widespread concern and potentially contributing to responsible alcohol consumption practices.
The clinical trial revealed a greater than 40% faster reduction in blood alcohol concentration within 30 minutes of consuming unbuzzd™ compared to the placebo group. Participants experienced a significant improvement in alertness, a stabilization of heart rate and blood pressure, and a 67% reduction in headache severity four hours after consuming the supplement. These effects were sustained over the four-hour monitoring period. The product is currently available for purchase through Celly Nutrition Corp., a company in which Quantum BioPharma holds a 25.71% stake and receives royalties on sales.
The successful trial results position unbuzzd™ for potential rapid market growth and solidify Quantum BioPharma’s position as an innovator in the biopharmaceutical space. Further research could explore the supplement’s long-term effects and potential applications in managing alcohol-related issues. While unbuzzd™ offers a promising approach to mitigating the effects of alcohol, it is crucial to emphasize that it does not eliminate impairment and should not be seen as a license to disregard responsible drinking practices or legal limitations regarding driving under the influence.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
